Study identifier:D1447C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase 3 study of the Efficacy & Safety of Quetiapine Fumarate & Lithium as Monotherapy in Adult Patients with Bipolar Depression for 8 weeks & Quetiapine in Continuation (abbreviated)
Bipolar Disorder
Phase 3
No
Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)
All
672
Interventional
18 Years - 65 Years
Allocation: Randomized 
Endpoint Classification: Efficacy Study 
Intervention Model: Parallel Assignment 
Masking: Double Blind 
Primary Purpose: Treatment 
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
| Arms | Assigned Interventions | 
|---|